Despite some limitations, the study provides directions for planning healthcare services for DMD in India by developing standard treatment guidelines, allocation of resources through national health schemes for carrier screening and prenatal diagnosis, promoting evidence-based therapeutic practices, and regulation to curb unscientific therapies. Baseline data are available to decide cost-effectiveness of public expenditure for disease-modifying drugs for DMD.
Antony et al. (Mon,) studied this question.